OncoSec Medical Incorporated (OTCBB: ONCS), which is developing its advanced-stage ElectroOncology therapies to treat solid tumor cancers, announced today that one of its clinical trial advisers will present results from an ElectroImmunotherapy clinical trial for melanoma at the 2011 American Society of Clinical Oncology Annual Meeting to be held June 4-8 at McCormick Place, Chicago, IL.
Dr. Adil Daud, a clinical trials adviser for Oncosec Medical, and Clinical Professor, Hematology/Oncology, University of California, San Francisco, will discuss trial results from a long-term, follow-up study of melanoma patients treated with DNA IL-12 delivered via electroporation. Dr. Daud will lead the following poster session:
Session: Developmental Therapeutics – Clinical Pharmacology and Immunotherapy
Discussion: “Systemic immune responses induced by intratumoral plasmid IL-12
electroporation in patients with melanoma”
Monday, June 6, 8:00 AM to 12:00 PM
Location: McCormick Place Hall A
OncoSec Medical Incorporated